HAL (France)open access
Patients with Cancer and Immune Checkpoint Inhibitor-Induced Rheumatic irAEs Treated by DMARDs: The RHUMICI Single-Centre Retrospective Cohort
Immune checkpoint inhibitors, Overall survival, Immune-related adverse events, 1, Oncological outcomes, 0, Real-world study, Disease-modifying antirheumatic drugs
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 922929
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.